ArticleScientific reports2025
Platelet apheresis with additive solution and plasma rinseback affects the cellular composition of LRS chamber products.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding the supply of human leukocytes for research by harvesting cell concentrates from Trima Accel tubing sets.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte concentrates recovered from leukocyte reduction system (LRS) chambers of the Trima Accel automated blood collection device are a by-product of platelet apheresis that is often used in research. The Trima Accel software was obligatorily updated in 2023 from version 6 to 7. Here, we investigated software-dependent differences in the cellular composition of LRS concentrates when performing apheresis with either plasma or platelet additive solution. When using plasma as suspension medium, the software update to Trima 7 led to higher fraction of B cells as revealed by flow cytometry. Compared to platelets-in-plasma collection, the total recovered volume and leukocyte density was significantly reduced when running Trima 7 software with platelet additive solution including a plasma rinseback. Moreover, the proportion of lymphocytes and monocytes in these products was lower, whereas the proportion of neutrophils and eosinophils was higher. Researchers working with leukocytes isolated from LRS chambers should be aware that performing apheresis with platelet additive solution alters the composition of their starting material, which could affect the interpretation of some experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.